Change search
ReferencesLink to record
Permanent link

Direct link
Phospho-Akt Immunoreactivity in Prostate Cancer: Relationship to Disease Severity and Outcome, Ki67 and Phosphorylated EGFR Expression
Umeå University, Faculty of Medicine, Department of Medical Biosciences.
Umeå University, Faculty of Medicine, Department of Pharmacology and Clinical Neuroscience.
Umeå University, Faculty of Medicine, Department of Medical Biosciences.
Umeå University, Faculty of Medicine, Department of Surgical and Perioperative Sciences.
Show others and affiliations
2012 (English)In: PLoS ONE, ISSN 1932-6203, Vol. 7, no 10, e47994- p.Article in journal (Refereed) Published
Abstract [en]

Background: In the present study, we have investigated the prognostic usefulness of phosphorylated Akt immunoreactivity (pAkt-IR) in prostate cancer using a well-characterised tissue microarray from men who had undergone transurethral resection due to lower urinary tract symptoms. Methodology/Principal Findings: pAkt-IR in prostate epithelial and tumour cells was assessed using a monoclonal anti-pAkt (Ser(473)) antibody. Immunoreactive intensity was determined for 282 (tumour) and 240 (non-mlignant tissue) cases. Tumour pAkt-IR scores correlated with Gleason score, tumour Ki67-IR (a marker of cell proliferation) and tumour phosphorylated epidermal growth factor receptor (pEGFR)-IR. For cases followed with expectancy, a high tumour pAkt-IR was associated with a poor disease-specific survival, and the prognostic information provided by this biomarker was additive to that provided by either (but not both) tumour pEFGR-IR or Ki67-IR. Upon division of the cases with respect to their Gleason scores, the prognostic value of pAkt-IR was seen for patients with Gleason score 8-10, but not for patients with Gleason score 6-7. Conclusions/Significance: Tumour pAkt-IR is associated with both disease severity and disease-specific survival. However, its clinical use as a biomarker is limited, since it does not provide prognostic information in patients with Gleason scores 6-7.

Place, publisher, year, edition, pages
2012. Vol. 7, no 10, e47994- p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:umu:diva-61971DOI: 10.1371/journal.pone.0047994ISI: 000310261800027OAI: diva2:578727
Available from: 2012-12-18 Created: 2012-12-04 Last updated: 2013-11-06Bibliographically approved

Open Access in DiVA

Phospho-Akt Immunoreactivity in Prostate Cancer(856 kB)89 downloads
File information
File name FULLTEXT02.pdfFile size 856 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Search in DiVA

By author/editor
Hammarsten, PeterCipriano, MariateresaJosefsson, AndreasStattin, PärFowler, Christopher J.
By organisation
Department of Medical BiosciencesDepartment of Pharmacology and Clinical NeuroscienceDepartment of Surgical and Perioperative SciencesPharmacology
In the same journal
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 89 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 76 hits
ReferencesLink to record
Permanent link

Direct link